A
Aureka Biotechnologies
Integrated digital biology and AI solutions to accelerate the discovery of new drugs and therapeutics, with a best-in-class technology platform ecosystem and an interdisciplinary team
About Aureka Biotechnologies
Aureka Biotechnologies is a biotech company that has developed an AI-powered platform for protein engineering and immunotherapeutic discovery. The company's platform integrates digital biology, artificial intelligence, and high-throughput, single-cell-based functional screening to accelerate the design of next-generation biologic and protein therapeutics.
Read full description
Aureka's business model is centered around co-discovery partnerships with established pharmaceutical and biotech companies. Through these collaborations, the company applies its technology to design novel antibody therapeutics for challenging targets. This approach has demonstrated success and has led to the establishment of multiple partnerships. The company serves clients in the pharmaceutical and biotechnology sectors that are looking to enhance their therapeutic discovery and development pipelines.
Aureka has developed a proprietary GPT-like large language model (LLM) for protein design, which is trained on its own protein/protein co-evolution data. This, combined with high-throughput parallel evolution experiments, allows for the rapid generation and screening of a diverse and focused library of potential therapeutics. The company has recently secured $10 million in seed funding to further advance its platform and expand its operations.
At a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Laguna Hills, United States
- Employees
- 34
- Open positions
- 2
- Dealroom signal
- 90.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Aureka Biotechnologies.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2026 | $35M | $140M | Matrix Partners China · Qiming Venture Partners · Newley Capital · HongShan | ↗ |
| SERIES AOther financing | Nov 2025 | $20M | $80M | Matrix Partners China · NewLight Capital · Qiming Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Aureka Biotechnologies is 5.9K monthly website visits, up 90.3% over the last three months. Aureka Biotechnologies's team grew 36% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- NCNewley Capital
- XCXianfeng Cowin
- DCDevice of Tomorrow Capital
Series A8 investors entered at this stage
- K2K2VC
NRL Capital
Matrix Partners China
Qiming Venture Partners
NewLight Capital
HongShan
5Y Capital
Boyuan Capital
Other known investors1 additional known investor
University of California, Irvine
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aureka Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aureka Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.